Absorption Systems is a world leader in several areas,” said Dr. Bhoopathy, “and I’m really excited about continuing to grow the company’s top line and bottom line, and further enhancing its reputation for scientific excellence
Exton, PA (PRWEB) April 28, 2011
Absorption Systems, a leader in testing drugs for ADMET (absorption, distribution, metabolism, excretion and toxicity) and medical devices for efficacy and safety, today announced the promotion of.Sid Bhoopathy, Ph.D. from VP of Operations to Chief Operating Officer. Dr. Bhoopathy has been instrumental in the growth and development of Absorption Systems and has held various positions within the company since 2004. In his expanded role, Dr. Bhoopathy has overall responsibility for strategic leadership and day-to-day operations in sales; marketing; and planning, execution and delivery of contract services. Dr. Bhoopathy is based at the company’s Exton, PA headquarters.
“Sid has proven his considerable value to the company in his seven years with us, and has been rewarded with steadily increasing levels of responsibility along the way,” said Patrick M. Dentinger, President and CEO of Absorption Systems. “As Chief Operating Officer his passion, focus and drug development savvy will help us execute our shared vision for the future of Absorption Systems.”
Previously, Dr. Bhoopathy was a research scientist at PPDI, focusing on developing and validating GLP analytical methods and performing metabolite identification using high-resolution mass spectrometry. He received his Ph.D. in pharmaceutics from Virginia Commonwealth University. His current research interests are in the areas of blood-brain barrier (BBB), Biopharmaceutics Classification System (BCS) and drug transporters.
“Absorption Systems is a world leader in several areas,” said Dr. Bhoopathy, “and I’m really excited about continuing to grow the company’s top line and bottom line, and further enhancing its reputation for scientific excellence.”
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit http://www.absorption.com.
# # #